TriangleOdetiglucan (NCT07199764)
Odetiglucan trial for Pancreatic Ductal Adenocarcinoma (NCT07199764). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable locally advanced or metastatic pancreatic adenocarcinoma, stable or partly responding after sixteen to thirty-two weeks of first-line chemotherapy.
The idea: maintenance odetiglucan and mitazalimab aim to stimulate immune cells against cancer. Both are infused every three weeks. Biopsies are required when accessible and medically feasible. Researchers assess progression-free survival. Fifty patients receive treatment; a separate group is observed without study drugs. Assignment is not random.
This phase 2 study plans 100 patients. The University of Pennsylvania sponsors it; Philadelphia is the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.